MimiVax awarded Orphan Drug Designation by US FDA for SurVaxM to treat glioblastoma patients
Novel immunotherapy, SurVaxM, being developed as treatment for glioblastoma BUFFALO, N.Y. — The U.S. Food and Drug Administration has awarded orphan drug status to a promising immunotherapy vaccine developed at…